Experimental and Clinical Gastroenterology最新文献_第6页

Cholelithiasis in a patient with hereditary spherocytosis 一名遗传性球形红细胞增多症患者的胆石症

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-229-233

A. E. Shklyaev, V. V. Zaitseva, A. Bessonov, V. M. Dudarev

引用次数: 0

Butyric acid and its perspectives in control of obesity 丁酸及其在控制肥胖症方面的前景

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-88-94

A. S. Teplova, T. Demidova, T. N. Korotkova

{"title":"Butyric acid and its perspectives in control of obesity","authors":"A. S. Teplova, T. Demidova, T. N. Korotkova","doi":"10.31146/1682-8658-ecg-218-10-88-94","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-88-94","url":null,"abstract":"Butyric acid (BA, butyrate) is a short-chain fatty acid (SCFA) - a metabolite of the human gut microbiota (GM). This SCFA is represented in a larger amount relative to other SCFAs and is synthesized by butyrate-producing representatives of GM via various pathways. The substrate for the synthesis of BA is some food products, mainly starch and to a lesser extent dairy products. The synthesis of BA is directly or indirectly influenced by various factors, including dietary habits, antibacterial therapy, as well as harmful habits (smoking, alcohol abuse). Numerous data confirm the important role of BA in various metabolic processes. The effects of BA are of particular relevance in endocrinology as one of the potential mechanisms for controlling carbohydrate metabolism and body weight. Given the large amount of data on the correlation of an increase in the level of BA with the positive dynamics of metabolic parameters, as well as the presence of a wide range of pleiotropic effects of BA, it is interesting to study ways to control the metabolism of GM and, in particular, the production of BA. At the moment, there is no doubt about such method as the modification of nutrition. The use of dietary fiber, transplantation of fecal microbiota and the use of genetic engineering methods to improve the butyrate-producing properties of bacteria are actively discussed. Nevertheless, there are no unambiguous recommendations regarding the most effective way to manage the level of BA as an element of the treatment and prevention of obesity.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"120 S7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140237860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Morphofunctional characteristics of the liver and pancreas under the influence of the hepatoprotector “Remaxol” against the background of acute alcohol damage in rats 大鼠急性酒精损伤背景下肝保护剂 "雷美舒尔 "影响下的肝脏和胰腺形态功能特征

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-216-220

T. G. Glushkova, S. I. Lentsova, M. A. Gorbunova

{"title":"Morphofunctional characteristics of the liver and pancreas under the influence of the hepatoprotector “Remaxol” against the background of acute alcohol damage in rats","authors":"T. G. Glushkova, S. I. Lentsova, M. A. Gorbunova","doi":"10.31146/1682-8658-ecg-218-10-216-220","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-216-220","url":null,"abstract":"The goal. To study the effect of hepatoprotective drug “Remaxol” on morphology of the liver and pancreas as well as on blood serum indices in rats with alcohol damage. Materials and Methods. The study was conducted on mature male white laboratory rats divided into three groups: the first (control group) - intact animals, the second and third (experimental groups) - daily part of the rats received 40 % aqueous ethanol solution (96 % ethanol in a dose of 8ml/kg weight) for 7 days, then part of the rats from the experimental group were injected “Remaxol” in a dose 5 mg/kg weight daily for 7 days. Morphological study of the liver and its macrostructure was carried out; diameters of hepatocytes, sinusoid capillaries and pancreatic acini in animals of the control and experimental groups were measured; general and biochemical blood parameters were assessed. Results. Blood tests demonstrated acute alcohol poisoning in experimental groups (leukocytosis); short-term (7 days) alcohol damage had less effect on the size of hepatocytes than on the size of pancreatic acini; pancreatic acini were more reactive on toxic influence of alcohol; in the liver and pancreas there were signs of inflammatory reaction (cell swelling, lymphocytes infiltration). Conclusion. Histological picture of the liver and pancreas of the animals with acute alcohol poisoning on the background of “Remaxol” treatment showed a decrease in the toxic effect of 40 % alcohol on hepatocytes and pancreatocytes, normalization of their morphological parameters.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"23 52","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathomorphosis of ulcerative colitis: from body weight deficiency to sarcopenic obesity 溃疡性结肠炎的病理蜕变：从体重不足到肌无力性肥胖

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-57-62

G. Bikbavova, M. Livzan, N. S. Lisyutenko, A. E. Romanyuk

{"title":"Pathomorphosis of ulcerative colitis: from body weight deficiency to sarcopenic obesity","authors":"G. Bikbavova, M. Livzan, N. S. Lisyutenko, A. E. Romanyuk","doi":"10.31146/1682-8658-ecg-218-10-57-62","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-57-62","url":null,"abstract":"In recent decades, there has been a steady increase in the number of patients with non-communicable chronic diseases in developed economic countries, which include all nosologies of metabolic syndrome and chronic inflammatory diseases. To date, there is no doubt that pro-inflammatory pathogenetic mechanisms and changes in intestinal microbiocenosis associated with obesity are promoters of many non-communicable diseases. The “Westernized” style of nutrition influences the intraspecific qualitative and quantitative diversity of the intestinal microbiome, leading to a change in the permeability of the intestinal barrier and triggering an immune response. Recent studies show that about 15-40 % of patients with inflammatory bowel diseases (IBD) are obese, and another 20-40 % are overweight. The coexistence of inflammation, obesity and metabolic syndrome in patients with ulcerative colitis is becoming more and more frequent, meanwhile, there is a discrepancy between the severity of the disease and weight indicators, which may be unchanged and even exceed the norm. The effects associated with sarcopenia and sarcopenic obesity negatively affect the quality of life of patients with ulcerative colitis and long-term results. Sarcopenia acts as an independent predictor of surgical interventions in patients with IBD, is associated with high activity of the disease and with a higher frequency of postoperative complications, and is also a marker of the need for escalation of therapy. The general mechanisms of development indicate that the management of these conditions should be considered in a complex.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140241315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peculiarities of pharmacological prevention strategy of pancreatic complications after endoscopic papillosphincterotomy for choledocholithiasis 胆总管结石内镜乳头括约肌切开术后胰腺并发症药物预防策略的特殊性

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-197-201

S. Styazhkina, T. R. Spiridonov, T. O. Eltsov, E. D. Novikova

{"title":"Peculiarities of pharmacological prevention strategy of pancreatic complications after endoscopic papillosphincterotomy for choledocholithiasis","authors":"S. Styazhkina, T. R. Spiridonov, T. O. Eltsov, E. D. Novikova","doi":"10.31146/1682-8658-ecg-218-10-197-201","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-197-201","url":null,"abstract":"The most frequent complication of endoscopic papillosphincterotomy (EPST) is acute pancreatitis. This complication is supposed to be based on mechanical, chemical, hydrostatic, enzymatic and thermal impact on pancreatic ducts and parenchyma. According to different literature data, the incidence of post-EPST pancreatitis (PEP) varies from 30 to 40%, and the mortality rate is 2-10%. The aim of the investigation was to expand information about peculiarities of early diagnostics and prevention of post-EST pancreatitis at the present stage. To reach the set goal we analyzed 559 case histories of patients with diagnosed cholelithiasis, 319 of them underwent EPST. During the study it was found out, that elevated neutrophils/lymphocytes ratio over 4,96 (p=0,001), high LDH level over 250 IU/ml (p=0,01), as well as C-reactive to albumin index over 0,180 (p=0,001) are reliable markers of early diagnosis. Also, indirect diagnostic markers of PEEP are biochemical signs of cholestasis and cytolysis of hepatocytes, as well as hyperglycemia combined with glucosuria. We consider the inclusion of intraoperative injections of papillotomy wound margins with Epinephrine in combination with subsequent Somatostatin administration in combination with rectal Diclofenac and intravenous hydration with Reamberin to be the most effective strategy for PEP prevention. Thus, we can conclude that despite the ongoing research and the search for effective algorithms for the prevention and early diagnosis of PEP, their data often contradict each other or simply do not confirm their effectiveness. The problem of prevention and diagnosis of PEP remains complex and requires further study. There are discrepancies, sometimes significant ones, in the current literature, which provides grounds for the development and research of new methods of early diagnosis and prevention.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"7 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140239772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the contribution of UGT1A gene polymorphisms to the development of cholelithiasis 评估 UGT1A 基因多态性对胆石症发病的影响

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-133-138

E. V. Shreiner, A. I. Khavkin, M. S. Novikova, N. Kokh, M. Denisov, G. Lifshits

引用次数: 0

Eating behavior in patients with metabolically associated fatty liver disease 代谢性脂肪肝患者的饮食行为

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-104-113

A. A. Khalashte, E. A. Lyalyukova, S. K. Zhachemuk, Z. A. Beslangurova, G. N. Zhernakova

{"title":"Eating behavior in patients with metabolically associated fatty liver disease","authors":"A. A. Khalashte, E. A. Lyalyukova, S. K. Zhachemuk, Z. A. Beslangurova, G. N. Zhernakova","doi":"10.31146/1682-8658-ecg-218-10-104-113","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-104-113","url":null,"abstract":"The purpose of this study was to study the phenotypes of eating behavior in patients with NAFLD and their determining factors. Discussion: fatty liver disease has a high prevalence (24-26%) with an upward trend in both developed and developing countries, and in the coming years may become one of the main causes of liver transplantation. The clinical features of the disease are in most cases its asymptomatic course, which can progress to fibrosis/cirrhosis and is associated with the risk of a number of serious extrahepatic diseases (cardiovascular, oncological and others). The mechanisms underlying the formation of increased health risks and disease prognosis are multifactorial. Metabolic disorders, orthorexia nervosa, eating disorders and vegetative effects are considered as possible pathogenetic mechanisms for increasing the risk of NAFLD incidence. Conclusion: the study showed that complex behavioral psycho-social factors are involved in the pathogenesis of NAFLD, and changing eating behavior is an important component of therapy. Dysfunctional eating behavior can be a barrier to long-term success from therapy.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140238878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity: current state of the problem, multidisciplinary approach. (based on the consensus of the World Gastroenterological Organization “Obesity 2023” and the European guideline on obesity care in patients with gastrointestinal and liver diseases, 2022) 肥胖症：问题现状，多学科方法。(根据世界胃肠病学组织 "肥胖症 2023 "共识和欧洲胃肠道和肝脏疾病患者肥胖症护理指南，2022 年）。

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-5-47

M. Livzan, E. A. Lyalyukova, I. Druk, S. S. Safronova, A. A. Khalashte, K. A. Martirosian, V. Y. Petrosian, Ya. S. Galakhov

{"title":"Obesity: current state of the problem, multidisciplinary approach. (based on the consensus of the World Gastroenterological Organization “Obesity 2023” and the European guideline on obesity care in patients with gastrointestinal and liver diseases, 2022)","authors":"M. Livzan, E. A. Lyalyukova, I. Druk, S. S. Safronova, A. A. Khalashte, K. A. Martirosian, V. Y. Petrosian, Ya. S. Galakhov","doi":"10.31146/1682-8658-ecg-218-10-5-47","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-5-47","url":null,"abstract":"Obesity is the largest pandemic in the world, and its prevalence continues to increase. The purpose of the presented publication is to raise awareness of doctors about modern methods of diagnosing obesity and approaches to therapy, using an interdisciplinary team approach similar to that used in other chronic diseases, such as diabetes, heart disease and cancer. The article presents data from the World Gastroenterological Organization (2023) and the European Guidelines for the Treatment of Obesity in patients with diseases of the gastrointestinal tract and liver (2022). According to modern approaches, obesity should be considered as a chronic recurrent progressive disease, the treatment of which requires a comprehensive interdisciplinary approach involving psychologists and psychiatrists, nutritionists/nutritionists, therapists, endoscopists and surgeons, including lifestyle changes, a well-defined diet and exercise regimen, drug therapy, endoscopic or surgical methods of treatment. Conclusions. In order to stop the growing wave of obesity and its many complications and costs, doctors, insurance companies and health authorities should make systematic efforts to raise public awareness of both the adverse health risks associated with obesity and the potential reduction of risks through a comprehensive approach to therapy.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"24 41","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological models of liver iron overload 肝脏铁负荷过重的药理模型

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-221-228

T. E. Bogacheva, I. Torshin, O. Gromova, T. R. Grishina

{"title":"Pharmacological models of liver iron overload","authors":"T. E. Bogacheva, I. Torshin, O. Gromova, T. R. Grishina","doi":"10.31146/1682-8658-ecg-218-10-221-228","DOIUrl":"https://doi.org/10.31146/1682-8658-ecg-218-10-221-228","url":null,"abstract":"Iron deposits in tissues (hemosiderosis) accompany various diseases of the liver and pancreas. Overload of the liver with iron occurs due to (1) a diet with excess saturated fats, which provoke inflammation of the liver, (2) slowdown and stagnation of blood flow in the area of the portal vein (physical inactivity, obesity, alcoholism, etc), (3) uncontrolled and long-term use of iron supplements (primarily based on inorganic forms - sulfates, oxides, hydroxides of iron, etc.), (4) hereditary diseases (hemochromatosis). Patients with liver overload with iron require not only correction of diet and lifestyle (including physical activity), but also special therapy using effective and safe drugs. To study the effect of excess iron on the body and search for the most appropriate therapy for hemosiderosis, special models of liver overload with iron have been developed in pharmacology. The degree of iron overload and the rate of hemosiderosis formation in models can be slowed down by the addition of micronutrients with hepatoprotective properties (vitamins A, C) and accelerated by the addition of saturated fat and/or fructose to the diet.","PeriodicalId":12262,"journal":{"name":"Experimental and Clinical Gastroenterology","volume":"11 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140241064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD) 脂肪因子在代谢相关性脂肪肝（MAFLD）条件下形成代谢紊乱中的作用

Experimental and Clinical Gastroenterology Pub Date : 2024-03-15 DOI: 10.31146/1682-8658-ecg-218-10-168-174

M. Livzan, T. Krolevets, M. I. Syrovenko

引用次数: 0